People · Operator
Named in public records as an officer, director or promoter · active 2022–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. | — | Pharmaceuticals | Series C | $139.5M | $972.1M | 2022 |
MUTYA HARSCH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MUTYA HARSCH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Perlman | 1 | 15 |
| Anthony Bruno | 1 | 4 |
| Edward Schnipper | 1 | 4 |
| Steven Basta | 1 | 3 |
| James Larrick | 1 | 2 |
| Albert L. Cha | 1 | 2 |
| Ketan L. Patel | 1 | 2 |
| Steven L. Basta | 1 | 2 |
| Scott L. Whitcup | 1 | 1 |
| Aaron L. Royston | 1 | 1 |
| Ted L. Ebel | 1 | 1 |
| David L. Collier | 1 | 1 |
| SHARON BARBARI | 1 | 1 |
| TYLER ZERONDA | 1 | 1 |
| DAVID DOMZALSKI | 1 | 1 |
| ELISABETH SANDOVAL | 1 | 1 |
| PATRICK LEPORE | 1 | 1 |
| IAIN STUART | 1 | 1 |
| John L. Creecy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.